Stephen Krieger, MD

August 10, 2022

Experts in neurology share practice pearls to optimize the treatment for patients with multiple sclerosis.

August 10, 2022

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their excitement for the future of multiple sclerosis treatment and comment on emerging therapies.

August 10, 2022

Experts in neurology provide insight into treatment selection and sequencing in patients with multiple sclerosis, focusing on S1P modulators.

August 05, 2022

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered an overview of the State of the Science Summit that was held on June 30, 2022, with a variety of expert clinicians from Mount Sinai. [WATCH TIME: 7 minutes]

August 03, 2022

Dr Jacqueline Nicholas hypothesizes about the utility of neurofilaments as a biomarker of disease severity in patients with multiple sclerosis.

August 03, 2022

Heidi Crayton, MD, and Jacqueline Nicholas, MD, review the importance of long-term safety data in the management of patients with multiple sclerosis, and Flavia Nelson, MD, discusses her approach to counseling patients on the safety considerations regarding new S1P modulating agents.

July 27, 2022

Dr Flavia Nelson comments on the impact of S1P modulators on brain volume measures; highlighting thalamic atrophy and its correlation with brain volume loss in MS.

July 27, 2022

Experts in neurology review data surrounding the role of disease-modifying therapies in preventing grey matter brain atrophy and cognitive decline.

July 20, 2022

Dr Heidi Crayton discusses the role of S1P receptor modulators in the management of patient with multiple sclerosis.

July 20, 2022

Flavia Nelson, MD, provides an overview of available brain atrophy data and cognition research in patients with multiple sclerosis.